Jared Kaltwasser

Forty-two percent of patients in the cohort had an adverse pregnancy outcome.

The analysis suggests the marker could be used to screen patients for potential immunotherapy.

Body mass index did not appear to correlate with glycemic control, the study found.

Patients with higher levels of interferon-β (IFNβ) in their B cells were less likely to have oral and nasal ulcers or photosensitivity.

A panel of experts suggests adding caplacizumab to the historic treatment of plasma exchange and immunosuppression could lead to significant improvement in outcomes for patients with immune-mediated thrombotic thrombocytopenic purpura (iTTP).

The study suggests blood pressure and cholesterol medications may be appropriate for some younger patients in order to prevent renal complications.

The findings could lead to new insights into how type 1 diabetes develops.

Patients of Asian heritage were also more likely to have end-organ manifestation, the authors found.

The microenvironment of the skin also helps explain why certain ethnicities appear to have a higher risk of melanoma.

In some cases, however, the rate of decline is no different than that of the general population, according to new research.

The pain, planning, emotional health, and fatigue quality of life domains were most impacted as a result of severe systemic lupus erythematosus (SLE) flares.

Patients with cold agglutinin disease faced a 4.5-times greater risk of death during winter months, new data show.

A survey of patients and health care providers found both groups favor at-home administration of biologics when possible.

Experts warn, however, that human papillomavirus (HPV) vaccinations missed because of the COVID-19 pandemic could stymie this progress.

All patients said insulin pump therapy helped their diabetes management related to exercise.

The study found associations between miRNA-499 polymorphism and autoimmune disease risk in Caucasian and Asian populations, including a significantly increased risk of rheumatoid arthritis and systemic lupus erythematosus.

The drug yielded partial responses in 2 of 15 patients in this single-arm, phase 2 study.

Data from this new study suggest melanoma cases rose at a slower rate in lower-income countries, but the authors say that may be due to differences in case documentation.

This new research may help investigators prevent skin lesions.

More experienced dermatopathologists were less likely to see overdiagnosis as a significant public health problem, a new survey showed.

The study highlights differences between patients with systemic lupus erythematosus (SLE) and healthy controls, potentially shedding light on the disease’s underlying mechanisms.

A subsequent analysis suggested, however, that segmentectomy was preferable to lobectomy in many cases.

Investigators found quality of life (QOL) effects may be tied to patients’ perceptions of cognitive impairment, rather than objective measurements of impairment from systemic lupus erythematosus (SLE).

Investigators found 6 genes associated with cancer-associated fibroblasts that appear to correlate with response to anti-PD-1 immunotherapy.

In patients with liver involvement, intrahepatic cholangiocarcinoma was a common diagnosis among some patients with cancer of unknown primary (CUP).

Although classic methods of risk stratification still hold value, the authors said genetic analysis holds significant promise.

The study showed that introducing the TLR7 variant in an animal model led to the development of autoimmune symptoms and potential development of systemic lupus erythematosus (SLE).

Among a cohort of 88 patients with acute myeloid leukemia who received hypomethylating agents with venetoclax prior to allogeneic hematopoietic cell transplant, 85% had achieved morphologic complete response at 100 days.

A new commentary suggests new pathways might lead to a major shift in the treatment of pulmonary arterial hypertension (PAH).

The finding is important because evidence suggests it is becoming more common for patients to receive care from a general practitioner for skin cancer, versus a surgeon or dermatologist.